Literature DB >> 15066239

Evolving Treatment Strategies for Carotid Artery Stenosis.

Renee Bailey Van Stavern1, Seemant Chaturvedi.   

Abstract

Internal carotid artery stenosis is an important cause of ischemic stroke. Treatment decisions frequently center on whether the patient is symptomatic or asymptomatic. For recently symptomatic patients with severe stenosis (70% to 99%) and low to medium surgical risk, carotid endarterectomy (CEA) is extremely useful for stroke prevention. CEA is moderately useful for patients with 50% to 69% symptomatic stenosis and is not indicated for patients with symptomatic stenosis of less than 50%. CEA may be useful for select patients with severe asymptomatic stenosis (80% to 99%) but only if the surgical complication is kept below the 3% level. Carotid stenting is an emerging option for the future but is still experimental. In addition to carotid intervention, patients with carotid stenosis should receive aggressive risk factor management, including treatment with antiplatelet agents and statins.

Entities:  

Year:  2004        PMID: 15066239     DOI: 10.1007/s11936-004-0038-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  41 in total

Review 1.  Cerebrovascular disease.

Authors:  P A Wolf; J C Grotta
Journal:  Circulation       Date:  2000-11-14       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis.

Authors:  G S Roubin; G New; S S Iyer; J J Vitek; N Al-Mubarak; M W Liu; J Yadav; C Gomez; R E Kuntz
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

4.  Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics.

Authors:  D E Wennberg; F L Lucas; J D Birkmeyer; C E Bredenberg; E S Fisher
Journal:  JAMA       Date:  1998 Apr 22-29       Impact factor: 56.272

5.  PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected].

Authors:  B Neal; S MacMahon
Journal:  J Hypertens       Date:  1995-12       Impact factor: 4.844

Review 6.  Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature.

Authors:  Andreas Kastrup; Klaus Gröschel; Hilmar Krapf; Bernhard R Brehm; Johannes Dichgans; Jörg B Schulz
Journal:  Stroke       Date:  2003-02-13       Impact factor: 7.914

7.  Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the Stroke Council of the American Heart Association.

Authors:  P A Wolf; G P Clagett; J D Easton; L B Goldstein; P B Gorelick; M Kelly-Hayes; R L Sacco; J P Whisnant
Journal:  Stroke       Date:  1999-09       Impact factor: 7.914

8.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study.

Authors:  B M Psaty; C D Furberg; L H Kuller; M Cushman; P J Savage; D Levine; D H O'Leary; R N Bryan; M Anderson; T Lumley
Journal:  Arch Intern Med       Date:  2001-05-14

9.  Precursors of extracranial carotid atherosclerosis in the Framingham Study.

Authors:  J S Fine-Edelstein; P A Wolf; D H O'Leary; H Poehlman; A J Belanger; C S Kase; R B D'Agostino
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

Review 10.  Blood pressure, antihypertensive treatment and stroke risk.

Authors:  S MacMahon; A Rodgers
Journal:  J Hypertens Suppl       Date:  1994-12
View more
  1 in total

1.  Risk factors and preventive measures of cerebral hyperperfusion syndrome after carotid artery interventional therapy.

Authors:  Shibo Wang; Jing Han; Lei Cheng; Nengpeng Li
Journal:  Exp Ther Med       Date:  2017-07-17       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.